Selected article for: "multiple inflammatory disease and present study"
Author: Augusti, Paula R.; Conterato, Greicy M.M.; Denardin, Cristiane C.; Prazeres, Inês D.; Serra, Ana Teresa; Bronze, Maria R.; Emanuelli, Tatiana
Title: BIOACTIVITY, BIOAVAILABILITY, AND GUT MICROBIOTA TRANSFORMATIONS OF DIETARY PHENOLIC COMPOUNDS: IMPLICATIONS FOR COVID-19
  • Cord-id: 417h29ex
  • Document date: 2021_6_2
    • ID: 417h29ex
    Snippet: The outbreak of mysterious pneumonia at the end of 2019 is associated with widespread research interest worldwide. The coronavirus disease-19 (COVID-19) targets multiple organs through inflammatory, immune, and redox mechanisms, and no effective drug for its prophylaxis or treatment has been identified until now. The use of dietary bioactive compounds, such as phenolic compounds (PC), has emerged as a putative nutritional or therapeutic adjunct approach for COVID-19. In the present study, scient
    Document: The outbreak of mysterious pneumonia at the end of 2019 is associated with widespread research interest worldwide. The coronavirus disease-19 (COVID-19) targets multiple organs through inflammatory, immune, and redox mechanisms, and no effective drug for its prophylaxis or treatment has been identified until now. The use of dietary bioactive compounds, such as phenolic compounds (PC), has emerged as a putative nutritional or therapeutic adjunct approach for COVID-19. In the present study, scientific data on the mechanisms underlying the bioactivity of PC and their usefulness in COVID-19 mitigation are reviewed. In addition, antioxidant, antiviral, anti-inflammatory, and immunomodulatory effects of dietary PC are studied. Moreover, the implications of digestion on the putative benefits of dietary PC against COVID-19 are presented by addressing the bioavailability and biotransformation of PC by the gut microbiota. Lastly, safety issues and possible drug interactions of PC and their implications in COVID-19 therapeutics are discussed.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • action mechanism and adjuvant therapeutic: 1, 2
    • action mechanism and adjuvant therapy: 1, 2, 3, 4
    • action mechanism and living cell: 1
    • action mechanism and low bioavailability: 1, 2
    • action mechanism and low concentration: 1, 2, 3, 4
    • action mechanism and low mortality: 1
    • action mechanism and lung epithelial cell: 1, 2
    • action mechanism and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and lung vascular: 1, 2, 3, 4
    • action mechanism and macrophage function: 1
    • action mechanism substance and low bioavailability: 1
    • activity mechanism and acute ards respiratory distress syndrome: 1
    • activity mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • activity mechanism and adjuvant therapy: 1
    • activity mechanism and low bioavailability: 1, 2
    • activity mechanism and lung epithelial cell: 1
    • activity mechanism and lung infection: 1
    • acute ards respiratory distress syndrome and adjuvant therapeutic: 1, 2, 3